HIV/AIDS epidemiology, pathogenesis, prevention, and treatment
The HIV-1 pandemic is a complex mix of diverse epidemics within and between countries
and regions of the world, and is undoubtedly the defining public-health crisis of our time …
and regions of the world, and is undoubtedly the defining public-health crisis of our time …
Biodegradable poly (lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens
Injectable biodegradable polymeric particles (usually microspheres) represent an exciting
approach to control the release of vaccine antigens to reduce the number of doses in the …
approach to control the release of vaccine antigens to reduce the number of doses in the …
V3: HIV's switch-hitter
The third variable region, V3, of the gp120 surface envelope glycoprotein is an
approximately 35-residue-long, frequently glycosylated, highly variable, disulfide-bonded …
approximately 35-residue-long, frequently glycosylated, highly variable, disulfide-bonded …
Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination
H Horton, EP Thomas, JA Stucky, I Frank… - Journal of …, 2007 - Elsevier
Candidate HIV-1 vaccines currently being evaluated in clinical trials are designed to elicit
HIV-1-specific cellular immunity. Intracellular cytokine staining (ICS) assays allow sensitive …
HIV-1-specific cellular immunity. Intracellular cytokine staining (ICS) assays allow sensitive …
The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly …
A Pinter, WJ Honnen, Y He, MK Gorny… - Journal of …, 2004 - Am Soc Microbiol
ABSTRACT A major problem hampering the development of an effective vaccine against
human immunodeficiency virus type 1 (HIV-1) is the resistance of many primary viral isolates …
human immunodeficiency virus type 1 (HIV-1) is the resistance of many primary viral isolates …
Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review
MP Girard, S Osmanov, OM Assossou, MP Kieny - Vaccine, 2011 - Elsevier
The development of a safe, effective and globally affordable HIV vaccine offers the best
hope for the future control of the HIV-1 pandemic. Since 1987, scores of candidate HIV-1 …
hope for the future control of the HIV-1 pandemic. Since 1987, scores of candidate HIV-1 …
A review of vaccine research and development: the human immunodeficiency virus (HIV)
MP Girard, SK Osmanov, MP Kieny - Vaccine, 2006 - Elsevier
Since the discovery of AIDS in 1981, the global spread of HIV has reached pandemic
proportions, representing a global developmental and public health threat. The development …
proportions, representing a global developmental and public health threat. The development …
Progress and obstacles in the development of an AIDS vaccine
NL Letvin - Nature Reviews Immunology, 2006 - nature.com
Recent experimental observations suggest approaches to immunization that might finally
result in at least a partially effective vaccine against infection with HIV-1. In particular …
result in at least a partially effective vaccine against infection with HIV-1. In particular …
HIV vaccine trial participation among ethnic minority communities: barriers, motivators, and implications for recruitment
Background: Underrepresentation of ethnic minority communities limits the generalizability
of HIV vaccine trial results. We explored perceived barriers and motivators regarding HIV …
of HIV vaccine trial results. We explored perceived barriers and motivators regarding HIV …
A sound rationale needed for phase III HIV-1 vaccine trials
DR Burton, RC Desrosiers, RW Doms, MB Feinberg… - Science, 2004 - science.org
The need for a human immunodeficiency virus-1 (HIV-1) vaccine [HN1] is unquestioned, and
we strongly support its development as the highest AIDS research priority. We have a …
we strongly support its development as the highest AIDS research priority. We have a …